Bayer unit gets rights to KYTHERA's adipolytic dermatology agent in up to $373 million deal; BTG to regain product rights from Nycomed

31 August 2010

German drugmaker Bayer HealthCare's (BAY. DE) dermatology business Intendis has entered an agreement with USA-based KYTHERA Biopharmaceuticals to develop and commercialize ATX-101; an adipolytic agent designed to reduce small volumes of facial fat through aesthetics' applications.

Under the terms of the deal, KYTHERA will receive an upfront payment of $43 million and may be eligible to receive cash payments upon the achievement of certain development, manufacturing and commercialization milestones totaling up to $330 million, as well as tiered, double digit royalties on net sales.

A Phase III study for the reduction of localized fat under the chin (submental fat) is expected to start in 2010 in Europe. Under the terms of the agreement, Intendis will receive the exclusive rights to commercialize ATX-101 outside the USA and Canada (which the US firm retains) and will collaborate with KYTHERA in the execution of the development ex-North America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK